Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells

Journal of Immunotherapy

Volumn 34, Issue 1, 2011, Pages 100-106

  Röllig, Christoph ^a   Schmidt, Christian ^a   Bornhäuser, Martin ^a   Ehninger, Gerhard ^a   Schmitz, Marc ^b   Auffermann Gretzinger, Susanne ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

dendritic cells; idiotype; immune response; stage I myeloma; vaccination

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; KEYHOLE LIMPET HEMOCYANIN; M PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER STAGING; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TH1 CELL; TH2 CELL;

ADULT; AGED; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HEMOCYANIN; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN IDIOTYPES; IMMUNOGLOBULINS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINS; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS;

EID: 78650644121     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181facf48     Document Type: Article

References (33)

1. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet. 2009;374:324-339.
2. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol. 2000;108: 805-816.
3. Inoges S, de Cerio AL, Soria E, et al. Idiotype vaccines for human B-cell malignancies. Curr Pharm Des. 2010;16:300-307.
4. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer. 2009;9: 675-681.
5. Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006;98:1292-1301.
6. Hollander N. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma. Crit Rev Immunol. 2009;29:399-418.
7. Osterborg A, Henriksson L, Mellstedt H. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma. Acta Oncol. 2000;39:797-800.
8. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer. 1999;83: 215-222.
9. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, et al. Idiotype vaccination using dendritic cells after auto-logous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2000;6: 621-627.
10. Reichardt VL, Milazzo C, Brugger W, et al. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica. 2003;88:1139-1149.
11. + monocytes positively selected by immuno-magnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol. 2003;121:240-250.
12. Abdalla AO, Kokhaei P, Hansson L, et al. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC). Ann Oncol. 2008;19:1172-1179.
13. Guardino AE, Rajapaksa R, Ong KH, et al. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma. Cytotherapy. 2006;8:277-289.
14. Wen YJ, Ling M, Bailey-Wood R, et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res. 1998;4:957-962.
15. Cull G, Durrant L, Stainer C, et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol. 1999;107: 648-655.
16. Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood. 1999;94: 673-683.
17. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood. 1999;93:2411-2419.
18. Coscia M, Mariani S, Battaglio S, et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia. 2004;18: 139-145.
19. Yi Q, Desikan R, Barlogie B, et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol. 2002;117:297-305.
20. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet. 1995;345:1016-1020.
21. Yi Q, Osterborg A. Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention? Med Oncol. 1996;13:1-7.
22. Osterborg A, Yi Q, Bergenbrant S, et al. Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br J Haematol. 1995;89: 110-116.
23. Yi Q, Osterborg A, Bergenbrant S, et al. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood. 1995;86:3043-3049.
24. Hansson L, Abdalla AO, Moshfegh A, et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res. 2007;13:1503-1510.
25. BD Biosciences Pharmingen. BDTM Cytometric Bead Array (CBA). Human Th1/Th2 Cytokine Kit Instruction Manual. Manual BD Biosciences Pharmingen. 2003.
26. Rasmussen T, Hansson L, Osterborg A, et al. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood. 2003;101:4607-4610.
27. Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompat-ibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood. 1998;91:2459-2466.
28. Abdalla AO, Hansson L, Eriksson I, et al. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients. Eur J Haematol. 2007;79:371-381.
29. Ikeda H, Chamoto K, Tsuji T, et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004;95:697-703.
30. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005;54:721-728.
31. Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by trans-forming growth factor-beta1 and interleukin-10. Blood. 2001;98:2992-2998.
32. Fiore F, Nuschak B, Peola S, et al. Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. Eur J Immunol. 2005;35:1155-1163.
33. Bendandi M, Rodriguez-Calvillo M, Inoges S, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allo-geneic stem cell transplantation. Leuk Lymphoma. 2006; 47:29-37.